The University of Southampton
University of Southampton Institutional Repository

Interaction with FcyRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody

Interaction with FcyRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody
Interaction with FcyRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody
A high activatory/inhibitory Fc?R binding ratio is critical for the activity of mAb such as rituximab and alemtuzumab that attack cancer cells directly and eliminate them by recruiting immune effectors. Optimal Fc?R binding profiles of other anti-cancer mAb, such as immunostimulatory mAb that stimulate or block immune receptors, are less clear. In this study, we analyzed the importance of isotype and Fc?R interactions in controlling the agonistic activity of the anti-mouse CD40 mAb 3/23. Mouse IgG1 (m1) and IgG2a (m2a) variants of the parental 3/23 (rat IgG2a) were engineered and used to promote humoral and cellular responses against OVA. The mouse IgG1 3/23 was highly agonistic and outperformed the parental Ab when promoting Ab (10-100-fold) and T cell (OTI and OTII) responses (2- to >10-fold). In contrast, m2a was almost completely inactive. Studies in Fc?R knockout mice demonstrated a critical role for the inhibitory Fc?RIIB in 3/23 activity, whereas activatory Fc?R (Fc?RI, -III, and -IV) was dispensable. In vitro experiments established that the stimulatory effect of Fc?RIIB was mediated through Ab cross-linking delivered in trans between neighboring cells and did not require intracellular signaling. Intriguingly, activatory Fc?R provided effective cross-linking of 3/23 m2a in vitro, suggesting the critical role of Fc?RIIB in vivo reflects its cellular distribution and bioavailability as much as its affinity for a particular Ab isotype. In conclusion, we demonstrate an essential cross-linking role for the inhibitory Fc?RIIB in anti-CD40 immunostimulatory activity and suggest that isotype will be an important issue when optimizing reagents for clinical use.
0022-1767
1754-1763
White, Ann L.
b8c81272-e959-4acb-bbfe-1adc8a6c43f0
Chan, H.T. Claude
b109c93f-7e9a-44ee-ad12-da757b1b11fc
Roghanian, Ali
e2b032c2-60a0-4522-a3d8-56a768792f36
French, Ruth R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Mockridge, C. Ian
327aef17-4837-4f2a-a93b-3d17cd1a7f9f
Tutt, Alison L.
46ce577b-aea1-412d-84ea-fc4dab794469
Dixon, Sandra V.
3d5b061e-0e17-4437-9d10-659330869410
Ajona, Daniel
8f27b4c2-475f-438f-9a67-59d5c40f87aa
Verbeek, J. Sjef
115ffb7c-4760-444f-888c-0798469e0b9c
Al-Shamkhani, Aymen
0a40b3ce-9d71-4d41-9369-7212f0a84504
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Beers, Stephen A.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
White, Ann L.
b8c81272-e959-4acb-bbfe-1adc8a6c43f0
Chan, H.T. Claude
b109c93f-7e9a-44ee-ad12-da757b1b11fc
Roghanian, Ali
e2b032c2-60a0-4522-a3d8-56a768792f36
French, Ruth R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Mockridge, C. Ian
327aef17-4837-4f2a-a93b-3d17cd1a7f9f
Tutt, Alison L.
46ce577b-aea1-412d-84ea-fc4dab794469
Dixon, Sandra V.
3d5b061e-0e17-4437-9d10-659330869410
Ajona, Daniel
8f27b4c2-475f-438f-9a67-59d5c40f87aa
Verbeek, J. Sjef
115ffb7c-4760-444f-888c-0798469e0b9c
Al-Shamkhani, Aymen
0a40b3ce-9d71-4d41-9369-7212f0a84504
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Beers, Stephen A.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded

White, Ann L., Chan, H.T. Claude, Roghanian, Ali, French, Ruth R., Mockridge, C. Ian, Tutt, Alison L., Dixon, Sandra V., Ajona, Daniel, Verbeek, J. Sjef, Al-Shamkhani, Aymen, Cragg, Mark S., Beers, Stephen A. and Glennie, Martin J. (2011) Interaction with FcyRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. Journal of Immunology, 187 (4), 1754-1763. (doi:10.4049/jimmunol.1101135). (PMID:21742972)

Record type: Article

Abstract

A high activatory/inhibitory Fc?R binding ratio is critical for the activity of mAb such as rituximab and alemtuzumab that attack cancer cells directly and eliminate them by recruiting immune effectors. Optimal Fc?R binding profiles of other anti-cancer mAb, such as immunostimulatory mAb that stimulate or block immune receptors, are less clear. In this study, we analyzed the importance of isotype and Fc?R interactions in controlling the agonistic activity of the anti-mouse CD40 mAb 3/23. Mouse IgG1 (m1) and IgG2a (m2a) variants of the parental 3/23 (rat IgG2a) were engineered and used to promote humoral and cellular responses against OVA. The mouse IgG1 3/23 was highly agonistic and outperformed the parental Ab when promoting Ab (10-100-fold) and T cell (OTI and OTII) responses (2- to >10-fold). In contrast, m2a was almost completely inactive. Studies in Fc?R knockout mice demonstrated a critical role for the inhibitory Fc?RIIB in 3/23 activity, whereas activatory Fc?R (Fc?RI, -III, and -IV) was dispensable. In vitro experiments established that the stimulatory effect of Fc?RIIB was mediated through Ab cross-linking delivered in trans between neighboring cells and did not require intracellular signaling. Intriguingly, activatory Fc?R provided effective cross-linking of 3/23 m2a in vitro, suggesting the critical role of Fc?RIIB in vivo reflects its cellular distribution and bioavailability as much as its affinity for a particular Ab isotype. In conclusion, we demonstrate an essential cross-linking role for the inhibitory Fc?RIIB in anti-CD40 immunostimulatory activity and suggest that isotype will be an important issue when optimizing reagents for clinical use.

This record has no associated files available for download.

More information

e-pub ahead of print date: 8 July 2011
Published date: 15 August 2011
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 339295
URI: http://eprints.soton.ac.uk/id/eprint/339295
ISSN: 0022-1767
PURE UUID: ad86723a-d5f7-405d-9538-8e0670ef5b6d
ORCID for H.T. Claude Chan: ORCID iD orcid.org/0000-0003-0530-9480
ORCID for Ali Roghanian: ORCID iD orcid.org/0000-0003-1316-4218
ORCID for Aymen Al-Shamkhani: ORCID iD orcid.org/0000-0003-0727-4189
ORCID for Mark S. Cragg: ORCID iD orcid.org/0000-0003-2077-089X
ORCID for Stephen A. Beers: ORCID iD orcid.org/0000-0002-3765-3342

Catalogue record

Date deposited: 28 May 2012 13:56
Last modified: 15 Mar 2024 03:34

Export record

Altmetrics

Contributors

Author: Ann L. White
Author: H.T. Claude Chan ORCID iD
Author: Ali Roghanian ORCID iD
Author: Ruth R. French
Author: C. Ian Mockridge
Author: Alison L. Tutt
Author: Sandra V. Dixon
Author: Daniel Ajona
Author: J. Sjef Verbeek
Author: Mark S. Cragg ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×